Your quick, fun fix for all things medical! We're serving up the latest healthcare scoop in bite-sized episodes, perfect for on-the-go docs and medical pros. Stay in the know, get inspired, and let's shake up the healthcare world together!
Stop Antibiotics Early in Endocarditis? The POET II Trial
Can you stop antibiotics for endocarditis two weeks early? The POET II trial (NEJM 2026) tested a protocol-based stopping rule in 508 patients.In stable patients with left-sided endocarditis from streptococci, Staphylococcus aureus or Enterococcus faecalis, stopping antibiotics once the POET stabilization criteria were met cut treatment by about two weeks and met noninferiority for the composite of death, unplanned surgery and embolism at six months. Relapse rose from 1.6 to 5.1 percent, mostly manageable, with enough enterococcal signal to argue for caution there. This supports considering a shorter course in selected patients, with close follow-up and a frank discussion of relapse.Original article: https://doi.org/10.1056/NEJMoa2607887
28 Oct 2026
Metoprolol in COPD
The BRONCHIOLE trial found that adding metoprolol to standard care did not significantly reduce exacerbations, cardiovascular events, or death in patients with COPD and no heart disease. It also found no rise in hospitalized exacerbations or deaths. The practical takeaway: don't start a beta-blocker to treat COPD itself, but don't withhold one from a COPD patient who needs it for their heart.
Original article: Sundh J, et al. NEJM Evidence 2026. https://doi.org/10.1056/EVIDoa2600231
ABOUT THE STATE OF HEALTH
The State of Health helps you understand the most important news and research in healthcare and medicine. For more visit stateofhealth.care (https://www.stateofhealth.care)
FOLLOW US
Youtube: youtube.com/@medzcool (https://www.youtube.com/@medzcool)
Instagram: instagram.com/medzcool (https://www.instagram.com/medzcool/)
Threads: threads.net/@medzcool (https://www.threads.net/@medzcool)
19 Nov 2024
CRISPR-Based Therapy for Hereditary Angioedema
Explore groundbreaking advancements in treating hereditary angioedema with NTLA 2002, a revolutionary CRISPR-Cas9 therapy. Discover how this innovative one-time treatment significantly reduces attacks, offering hope for those affected by this rare condition. Original Article here (https://www.nejm.org/doi/full/10.1056/NEJMoa2405734).
ABOUT THE STATE OF HEALTH
The State of Health helps you understand the most important news and research in healthcare and medicine. For more visit stateofhealth.care (https://www.stateofhealth.care)
FOLLOW US
Youtube: youtube.com/@medzcool (https://www.youtube.com/@medzcool)
Instagram: instagram.com/medzcool (https://www.instagram.com/medzcool/)
Threads: threads.net/@medzcool (https://www.threads.net/@medzcool)
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
5.0 / 5
3 ratings
Spotify
5.0 / 5
4 ratings
Host of State of Health?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
